Evgen Pharma PLC Presentation of SFX-01 Data at ECTRIMS 2016 (3582J)
08 Settembre 2016 - 4:30PM
UK Regulatory
TIDMEVG
RNS Number : 3582J
Evgen Pharma PLC
08 September 2016
For immediate release 8 September 2016
Evgen Pharma plc
("Evgen Pharma" or "the Company")
Presentation of SFX-01 Data at ECTRIMS 2016
Evgen Pharma plc (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, is pleased to announce that the results of its
preclinical study of SFX-01 in various models of the relapsing
remitting form of multiple sclerosis will be presented on Friday 16
September 2016 at the 32(nd) Congress of the European Committee for
Treatment and Research in Multiple Sclerosis (ECTRIMS) in London.
The study focused on the comparison of SFX-01 with dimethyl
fumarate, the active principle in BG-12 which is marketed as
Tecfidera(R) .
The data from these preclinical studies are embargoed for poster
presentation at the conference. A late-breaking abstract of the
poster will be made available on the ECTRIMS website on Monday 12
September 2016.
The poster is entitled Efficacy of SFX-01, a sulforaphane-based
drug in experimental autoimmune encephalomyelitis and has the
poster number P1658. Its authors are Dr Ian Galea (Associate
Professor in Experimental Neurology, Faculty of Medicine,
University of Southampton), Dr Ian Copple (Lecturer, Institute of
Translational Medicine, University of Liverpool) and Dr David Howat
(Evgen's Chief Development Officer).
The concluding statement from the poster is: "SFX-01 appears to
be superior to BG-12 in the therapeutic EAE model. SFX-01 appears
to exert maximum effects later in the course of the disease by
enabling superior neurological recovery in the chronic stage after
relapse. SFX-01 is a promising drug candidate in MS, and warrants
further investigation."
Once presented, a copy of the poster will be made available on
Evgen Pharma's website, www.evgen.com.
Dr Stephen Franklin, CEO of Evgen Pharma, commented: "We are
delighted that our preclinical multiple sclerosis data has been
accepted as a late breaking abstract at this year's ECTRIMS
conference. The preclinical study compared Evgen Pharma's SFX-01
against dimethyl fumarate, the active within Biogen's Tecfidera(R)
which is currently the main oral therapy for the
relapsing-remitting form of multiple sclerosis with annualised
sales of approximately US$4bn. This early stage comparative data is
encouraging and we intend to accelerate the commercial appraisal of
this opportunity with a view to updating shareholders later this
year."
The 2016 ECTRIMS conference is being held on 14-17 September at
ExCel London, One Western Gateway, Royal Victoria Dock, London E16
1X.
Enquiries:
Evgen Pharma plc c/o +44 (0) 20
Dr Stephen Franklin, CEO 7466 5000
www.evgen.com
Buchanan
Mark Court, Sophie Cowles, Stephanie +44 (0) 20
Watson 7466 5000
Northland Capital Partners Limited
Matthew Johnson, Gerry Beaney, Margarita
Mitropoulou (Corporate Finance) +44 (0) 20
John Howes, Rob Rees (Corporate Broking) 3861 6625
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose
lead programmes are in breast cancer and subarachnoid haemorrhage,
a type of stroke. It is also carrying out preclinical work in
multiple sclerosis and has a clinical interest in prostate cancer.
The Company's core technology is Sulforadex(R), a method for
synthesising and stabilising the naturally occurring compound
sulforaphane and novel proprietary analogues based on sulforaphane.
The lead product, SFX-01, is a patented composition of synthetic
sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and is based
in Liverpool, UK, at the Liverpool Science Park. It joined the AIM
market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG. For further information please visit
www.evgen.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEALNPEAKKEFF
(END) Dow Jones Newswires
September 08, 2016 10:30 ET (14:30 GMT)
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Lug 2023 a Lug 2024